CompletedNCT00564954
A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)
Medication studyAges 6–12United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- Little Rock and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 86
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00564954
- Official title
Show the full official title
A Randomized, Multi-center, Double-blind, Cross-over Study Comparing the Efficacy and Safety of Focalin® XR 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting
Recruitment & locations
CompletedLittle Rock · Winter Park · Las Vegas
2 more locations
- Houston
- Lubbock
Questions about this study
Who is behind this study?
The study sponsor is Novartis Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Dex-methylphenidate hydrochloride extended-release (Focalin XR) and Placebo.
Who was this study for?
Listed age limits: 6 years to 12 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)